Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.

Jorge R GeorgakopoulosMichelle PhungArvin IghaniJensen Yeung

Published in: Journal of cutaneous medicine and surgery (2018)

Ixekizumab has shown to be a safe and effective therapeutic option for plaque psoriasis in real-world practice. It does not appear that patients experience more AEs in real-world clinics than those in clinical trials.

Keyphrases

clinical trial
end stage renal disease
primary care
clinical practice
ejection fraction
chronic kidney disease
newly diagnosed
healthcare
coronary artery disease
prognostic factors
peritoneal dialysis
randomized controlled trial
type diabetes
quality improvement
skeletal muscle
double blind